Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
01/11/2017 01/12/2017 01/13/2017 01/16/2017 01/17/2017 Date
1(c) 0.95(c) 0.93(c) 0.95(c) 0.93 Last
2 075 642 961 225 860 884 882 888 177 448 Volume
-0.99% -5.00% -2.11% +2.15% -2.11% Change
More quotes
Financials (€)
Sales 2016 0,74 M
EBIT 2016 -12,5 M
Net income 2016 -10,6 M
Debt 2016 1,47 M
Yield 2016 -
Sales 2017 -
EBIT 2017 -11,3 M
Net income 2017 -10,5 M
Debt 2017 10,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 57,1x
EV / Sales2017 0
Capitalization 40,8 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis, and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
01/07 NEOVACS : to participate in two upcoming investor events in the United States an..
01/06 NEOVACS : to participate in two upcoming investor events in the United States an..
01/05 NEOVACS : to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical ..
2016 NEOVACS : obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE..
2016 NEOVACS : obtains FDA Fast Track designation for IFN Kinoid in Lupus (SLE)
2016 NEOVACS : obtains FDA “Fast Track” designation for IFNa Kinoid in Lu..
2016 DGAP-NEWS : Neovacs obtains FDA 'Fast Track' designation for IFNα Kinoid i..
2016 NEOVACS : obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE..
2016 DGAP-NEWS : Neovacs signs production partnership with 3P Biopharmaceuticals, a l..
2016 NEOVACS : signs production partnership with 3P Biopharmaceuticals, a leading GMP..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Qtime:
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,70 €
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS17.28%43
INCYTE CORPORATION17.43%22 182
QUINTILES IMS HOLDINGS..1.46%18 995
CELLTRION, INC.--.--%10 650
LONZA GROUP AG5.05%9 643
ALKERMES PLC-0.22%8 428
More Results